Skip to main content
OpenTrials
Completed

NCT Number: NCT00700817

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes inadequately controlled with metformin alone.

The trial has been extended by 52 weeks. The extension will consist of two 26-week periods:

1. Week 27-52 after randomisation

- All subjects will continue receiving sitagliptin or liraglutide at unchanged dose and dosing regimen. 2. Week 53-78 after randomisation

* Subjects receiving sitagliptin at the end of week 52 after randomisation will discontinue sitagliptin and will be randomised 1:1 to liraglutide 1.2 mg/day or liraglutide 1.8 mg/day. Liraglutide will be initiated at a dose of 0.6 mg/day, and increased to 1.2 mg/day or 1.8 mg/day in weekly intervals. * Subjects receiving liraglutide 1.2 mg/day or 1.8 mg/day at the end of week 52 after randomisation will continue the treatment at unchanged dose and dosing regimen. Trial completion is planned for June 2010.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Novo Nordisk Investigational Site, Edmonton, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes
  • Treatment with metformin alone for at least three months
  • HbA1c (glycosylated haemoglobin A1c) 7.5-10.0% (both inclusive)
  • Body Mass Index (BMI) less than or equal to 45.0

Exclusion criteria

  • Previous treatment with insulin, glucagon like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors
  • Treatment with anti-diabetic drugs other than metformin within the last three months
  • Any serious medical condition
  • Females who are pregnant, have the intention of becoming pregnant or are breastfeeding

Treatment and study plan

liraglutide

Drug

1.2 mg once daily, subcutaneous (under the skin) injection

Sitagliptin

Drug

Tablets, 100 mg daily

metformin

Drug

Tablets, minimum 1500 mg daily

Primary outcomes

  1. Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26.

  2. Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 52.

  3. Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78

    Time frame: Week 0, Week 78

    Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 78.

  4. Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean Change in Glycosylated Haemoglobin A1c (HbA1c) from Week 52 to Week 78

Secondary outcomes

  1. Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 26

    Time frame: Week 0, Week 26

    Calculated as the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 26

  2. Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 52

  3. Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78

    Time frame: Week 0, Week 78

    Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 78. Based on the FAS.

  4. Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78

    Time frame: Week 0, Week 78

    Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 78. Based on the extension 2 FAS.

  5. Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 26

    Time frame: Week 0, Week 26

    Calculated as the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 26

  6. Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 52

  7. Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78

    Time frame: Week 0, Week 78

    Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 78. Based on the FAS.

  8. Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78

    Time frame: Week 0, Week 78

    Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 78. Based on the extension 2 FAS.

  9. Mean Change From Baseline in Body Weight at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in body weight at Week 26.

  10. Mean Change From Baseline in Body Weight at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in body weight at Week 52.

  11. Mean Change in Body Weight From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in body weight from Week 52 to Week 78.

  12. Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 26.

  13. Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 52.

  14. Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 78

    Time frame: Week 0, Week 78

    Calculated as an estimate of the mean change in fasting plasma glucose (FPG) from baseline to Week 78.

  15. Mean Change in Fasting Plasma Glucose (FPG) From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in fasting plasma glucose (FPG) Week 52 to Week 78.

  16. Mean Change From Baseline in Beta-cell Function at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in beta-cell function at Week 26.

    Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B).

  17. Mean Change From Baseline in Beta-cell Function at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in beta-cell function at Week 52.

    Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B).

  18. Mean Change in Beta-cell Function From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in beta-cell function from Week 52 to Week 78. Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B).

  19. Mean Change From Baseline in Total Cholesterol at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in total cholesterol at Week 26.

  20. Mean Change From Baseline in Total Cholesterol at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in total cholesterol at Week 52.

  21. Mean Change in Total Cholesterol From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in total cholesterol from Week 52 to Week 78

  22. Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 26.

  23. Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 52.

  24. Mean Change in Low-density Lipoprotein-cholesterol (LDL-C) From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in low-density lipoprotein-cholesterol (LDL-C) from week 52 to Week 78.

  25. Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 26.

  26. Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 52.

  27. Mean Change in High-density Lipoprotein-cholesterol (HDL-C) From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in high-density lipoprotein-cholesterol (HDL-C) from Week 52 to Week 78.

  28. Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 26.

  29. Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 52.

  30. Mean Change in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in very low-density lipoprotein-cholesterol (VLDL-C) from Week 52 to Week 78.

  31. Mean Change From Baseline in Triglycerides (TG) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 26.

  32. Mean Change From Baseline in Triglycerides (TG) at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 52.

  33. Mean Change in Triglycerides (TG) From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in triglycerides (TG) from Week 52 to Week 78.

  34. Mean Change From Baseline in Free Fatty Acids (FFA) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 26.

  35. Mean Change From Baseline in Free Fatty Acids (FFA) at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 52.

  36. Mean Change in Free Fatty Acids (FFA) From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in free fatty acids (FFA) from Week 52 to Week 78.

  37. Mean Change From Baseline in Apolipoprotein B at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 26.

  38. Mean Change From Baseline in Apolipoprotein B at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 52.

  39. Mean Change in Apolipoprotein B From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in apolipoprotein B (ApoB) from Week 52 to Week 78.

  40. Mean Change From Baseline in Highly Sensitive C-reactive Protein (hsCRP) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in highly sensitive C-reactive protein (hsCRP) at week 26.

  41. Mean Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at Week 26.

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in plasminogen activator inhibitor-1 (PAI-1) at Week 26.

  42. Mean Change From Baseline in Interleukin-6 (IL-6) at Week 26.

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in interleukin-6 (IL-6) at Week 26.

  43. Mean Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26.

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in N-terminal pro B-type Natriuretic Peptide (NT-proBNP) at Week 26.

  44. Mean Change From Baseline in Adiponectin at Week 26.

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in Adiponectin at Week 26.

  45. Mean Change From Baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26.

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26.

  46. Mean Change From Baseline in Von Willebrand Factor (vWf) at Week 26.

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in von Willebrand Factor (vWf) at Week 26. vWf is a blood glycoprotein involved in haemostasis.

  47. Mean Change From Baseline in Waist to Hip Ratio at Week 26.

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 26. The measure is assessed as the circumference of the waist divided by the circumference of the hip.

  48. Mean Change From Baseline in Waist to Hip Ratio at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 52. The measure is assessed as the circumference of the waist divided by the circumference of the hip.

  49. Mean Change in Waist to Hip Ratio From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in Waist to Hip Ratio from Week 52 to Week 78. The measure is assessed as the circumference of the waist divided by the circumference of the hip.

  50. Mean Change From Baseline in Waist Circumference at Week 26.

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 26

  51. Mean Change From Baseline in Waist Circumference at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 52.

  52. Mean Change in Waist Circumference From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in Waist Circumference from Week 52 to Week 78.

  53. Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in Systolic Blood Pressure (SBP) at Week 26

  54. Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in systolic blood pressure (SBP) at Week 52.

  55. Mean Change in Systolic Blood Pressure (SBP) From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in systolic blood pressure (SBP) from Week 52 to Week 78.

  56. Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 26.

  57. Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 52.

  58. Mean Change in Diastolic Blood Pressure (DBP) From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in diastolic blood pressure (DBP) from Week 52 to Week 78.

  59. Mean Change From Baseline in Pulse at Week 26

    Time frame: Week 0, Week 26

    Calculated as an estimate of the mean change from baseline in pulse at Week 26.

  60. Mean Change From Baseline in Pulse at Week 52

    Time frame: Week 0, Week 52

    Calculated as an estimate of the mean change from baseline in pulse at Week 52.

  61. Mean Change in Pulse From Week 52 to Week 78

    Time frame: Week 52, Week 78

    Mean change in pulse from Week 52 to Week 78.

  62. Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 26

    Time frame: Week 0, Week 26

    The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36.

  63. Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 52

    Time frame: Week 0, Week 52

    The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36.

  64. Mean Change in Overall Treatment Satisfaction (OTS) From Week 52 to Week 78

    Time frame: Week 52, Week 78

    The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36.

  65. Hypoglyceamic Episodes, Weeks 0-26

    Time frame: Weeks 0-26

    Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

  66. Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26

    Time frame: Weeks 0-26

    Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

  67. Hypoglyceamic Episodes, Weeks 0-52

    Time frame: Weeks 0-52

    Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

  68. Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-52

    Time frame: Weeks 0-52

    Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

  69. Hypoglyceamic Episodes, Weeks 0-78

    Time frame: Weeks 0-78

    Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

  70. Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-78

    Time frame: Weeks 0-78

    Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

  71. Hypoglycaamic Episodes, Weeks 52-78

    Time frame: Week 52-78

    Number of hypoglycaemic episodes from Week 52 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension

Important dates

Study start
2008
Primary completion
2009
Study completion
2010
First posted
Jun 19, 2008
Registry last updated
Mar 8, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.